• Total revenues of approximately $9.4 million for the first quarter of 2019 compared to $6.8 million for the first quarter of 2018.
• Net income of $6.6 million, or $0.51 per share, and non-GAAP Adjusted net income of $7.4 million, or $0.57 per share for the first quarter of 2019.
• Closed two financings deploying $11.2 million. Post quarter close deployed $5.0 million with potential additional add-on funding of $7.5 million to existing portfolio companies.
• Book value of $16.98 per share as of March 31, 2019 vs. $16.47 per share as of December 31, 2018.

– Read More –

• Total revenues of approximately $26.0 million for the fiscal year 2018 compared to $37.5 million for the fiscal year 2017.
• For the fiscal year 2018 net income attributable to SWK Stockholders of $6.2 million, or $0.47 per share, and non-GAAP adjusted net income attributable to SWK Stockholders of $6.8 million, or $0.52 per share.
• Total income producing assets (defined as finance receivables, marketable investments and investment in unconsolidated entity less non-controlling interests) were $167.1 million as of December 31, 2018, an 8.6% increase from December 31, 2017.
• Book value of $16.47 per share as of December 31, 2018 vs. $15.93 as of December 31, 2017.
• For the fiscal year 2017, earned a 10.4% adjusted return on tangible book value, excluding the deferred tax asset and GAAP provision for income tax.
• $20.2 million of cash plus $20.0 million of credit facility capacity available for deployment as of December 31, 2018.
• For the full year 2018, closed six financings deploying $71.3 million with an additional $18.8 million deployed through existing portfolio company milestones and add-ons.
• After the close of the fourth quarter, deployed $1.2 million into a syndicated financing and $10.0 million into a new term loan.

– Read More –

Dallas, TX, December 6, 2018 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, today announced that its Board of Directors has authorized the Company to repurchase up to an aggregate of $3,500,000 of the Company’s Common Stock from time to time until May 31, 2019 through a “10b5-1 trading plan” in compliance with Rule 10b-18 under the Securities Exchange Act of 1934. Repurchases pursuant to the program may not exceed an aggregate of approximately 3% of the issued and outstanding shares of Common Stock pursuant to the terms of the Stockholders’ Agreement by and among affiliates of Carlson Capital, LP and the Company dated August 18, 2014.

– Read More –

• Total revenues of approximately $5.9 million for the third quarter of 2018 compared to $5.5 million for the third quarter of 2017.
• Net loss attributable to SWK Shareholders of $ 5.7 million, or $0. 44 per share, and non-GAAP Adjusted net loss of $ 8.3 million, or $0. 64 per share for the third quarter of 2018.
• Closed one financing deploying $ 12.2 million with additional $ 9.3 million deployed through existing portfolio company milestones and add-ons.
• Post quarter end, deployed $9 million into a new transaction and executed one term sheet for $12.5 million, which is expected to close in the fourth quarter.
• Post quarter end, resolved two non-accrual positions. In October, Provant Health Solutions was acquired by Quest Diagnostics with SWK receiving $15.6 million of cash proceeds in the sale, with another $0.2 million expected in the near term. In November, ABT Molecular Imaging was sold to Best Cyclotron for aggregate consideration to be paid over ten years to SWK of $500 thousand cash plus a 10% royalty on sales. SWK has no further funding liabilities to either company.
• Total income producing assets (defined as finance receivables, marketable securities and investment in unconsolidated subsidiaries less non-controlling interests) were $166.8 million as of September 30, 2018.
• Book value of $16. 05 per share as of September 30, 2018 vs. $15.93 per share as of December 31, 2017.

– Read More –

• Total revenues of approximately $6.8 million for the second quarter of 2018 compared to $6.1 million for the second quarter of 2017.
• Net income attributable to SWK Stockholders of $3.7 million, or $0.28 per share, and non-GAAP Adjusted net income of $5.6 million, or $0.43 per share for the second quarter of 2018.
• Closed one financing during the quarter, deploying $7.6 million with additional $10.0 million deployed through existing portfolio company milestones and add-ons. Closed fourth financing year to date in July, bringing year to date capital deployment to $62.3 million.
• Raised $20 million revolving credit facility.
• Book value of $16.49 per share as of June 30, 2018 vs. $15.93 per share as of December 31, 2017.

Dallas, TX, August 10, 2018 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its second quarter 2018 financial results.

– Read More –

Dallas, TX, July 2, 2018 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced that it has closed a $20 million revolving credit facility with AloStar Capital Finance, a division of State Bank & Trust (“AloStar”).

– Read More –

• Total revenues of $6.8 million for the first quarter of 2018 compared to $14.9 million for the first quarter of 2017.
• Net income attributable to SWK Stockholders of $3.6 million, or $0.28 per share, and non-GAAP adjusted net income of $4.4 million, or $0.34 per share for the first quarter of 2018.
• Closed two financings deploying $25.0 million with additional $4.3 million deployed through existing portfolio company milestones and add-ons.  
• Book value of $16.21 per share as of March 31, 2018 vs. $15.93 per share as of December 31, 2017.

Dallas, TX, May 14, 2018 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its first quarter 2018 financial results.

– Read More –

SWK Holdings Corporation Announces 2017 Fourth Quarter and Full-Year Financial Results

• Total revenues of $37.5 million for the fiscal year 2017 compared to $22.4 million for the fiscal year 2016.
• For the fiscal year 2017, net income attributable to SWK Stockholders of $3.0 million, or $0.23 per share, and non-GAAP adjusted net income attributable to SWK Stockholders of $19.9 million, or $1.53 per share.
• Total income producing assets (defined as finance receivables, marketable investments and investment in unconsolidated entity less non-controlling interests) were $153.9 million as of December 31, 2017, a 16.4% increase from December 31, 2016.
• Book value of $15.93 per share as of December 31, 2017. For the fiscal year 2017, book value per share increased 11.7% after adjusting for the reduction in SWK’s deferred tax asset due to the decrease in the U.S. corporate tax rate.
• For the fiscal year 2017, earned a 10.4% adjusted return on tangible book value, excluding the deferred tax asset and GAAP provision for income tax.
• $30.6 million of cash and cash equivalents available for deployment as of December 31, 2017.
• For the full year 2017, closed three new financings deploying $25.8 million at a weighted average 16.0% GAAP projected effective yield and deployed an additional $16.7 million to existing portfolio partners.
• After the close of the fourth quarter, deployed $10.0 million into a new synthetic royalty financing, $15.0 million into a new term loan, and deployed an additional $3.3 million into two existing portfolio partners.

Dallas, TX, March 29, 2018 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its fourth quarter and full year 2017 financial results.

– Read More –

• Total revenues of approximately $5.5 million for the third quarter of 2017 compared to $4.2 million for the third quarter of 2016.
• Net income attributable to SWK Shareholders of $2.8 million, or $0.21 per share, and non-GAAP Adjusted net income of $4.0 million, or $0.31 per share for the third quarter of 2017.
• Closed two financings deploying $17.2 million with additional $8.3 million deployed through existing portfolio company milestones and add-ons.
• Book value of $16.62 per share as of September 30, 2017 vs. $15.67 per share as of December 31, 2016.

Dallas, TX, November 10, 2017 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its third quarter 2017 financial results.

– Read More –

• Total revenues of approximately $6.1 million for the second quarter of 2017 compared to $8.6 million for the second quarter of 2016.
• Net income attributable to SWK Shareholders of $3.4 million, or $0.26 per share, and non-GAAP Adjusted net income of $5.0 million, or $0.38 per share for the second quarter of 2017.
• Post quarter’s end, closed two financings deploying $17.2 million with additional $6.6 million deployed through existing portfolio company milestones and add-ons.
• Book value of $16.47 per share as of June 30, 2017 vs. $15.67 per share as of December 31, 2016.

Dallas, TX, August 10, 2017 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its second quarter 2017 financial results.

– Read More –